SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Valeant Pharmaceuticals International, Inc. (VRX)

NEW YORK, June 19, 2018

The investigation concerns whether Valeant and certain of its officers and/or directors have violated federal securities laws.

On June 18, 2018, Valeant's Ortho Dermatologics division announced receipt of a Complete Response Letter ("CRL") from the U.S. Food and Drug Administration regarding the company's New Drug Application for DUOBRII (halobetasol propionate and tazarotene) (IDP-118) lotion in the treatment of plaque psoriasis.  In a press release, Valeant's Chairman and Chief Executive Officer Joseph C. Papa stated that the CRL raised "questions regarding pharmacokinetic data".  Following this announcement, Valeant's share price fell $3.30, or 12.29%, to close at $23.56 on June 18, 2018.

If you are aware of any facts relating to this investigation, or purchased Valeant shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/vrx. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com